Baric Transcribed Interview (Redacted) — page 93

DC.Scheduling@LexitasLegal.com As part of the thought process, there were two questions. There were two ideas that came forward. One was why don't sarbecoviruses have furin cleavage sites. And I've studied coronaviruses all my life. I know sarbecoviruses. I've seen zoonotic strains. They don't have furin cleavage sites. MERS strains do. Human coronaviruses do. Feline coronaviruses do. Why don't sarbecos? There should be sarbecos out there that have furin cleavage sites, so they were going to look for them. Once they found them and they sequenced it they were going to work on it with pseudotypes. They were going to drop those spike genes into pseudotypes and ask what's -- we were also going to look at the receptor binding domain, obviously, and I think we hypothesized in there that there should be strains with 25 percent variation in spike that could still use the ACE2 receptor. And those are obviously of interest because if you're interested in developing pan18 sarbecovirus vaccines or drugs you want, in essence, the bookends of the heterogeneity that exists in the virus subgenus, right. You want strains that you know and strains that are very different, because you have no idea what would emerge in the future. So if you have breadth then you have a better chance of developing something that could be used immediately. So those are two major features. The first part would